Polyclonal Antibody to Procollagen I N-Terminal Propeptide (PINP) | MyBioSource MBS2001791 product information

product summary

company name :

MyBioSource

product type :

antibody

product name :

Polyclonal Antibody to Procollagen I N-Terminal Propeptide (PINP)

catalog :

MBS2001791

quantity :

0.01 mg

price :

115 USD

clonality :

polyclonal

host :

rabbit

conjugate :

nonconjugated

reactivity :

rat

application :

western blot, immunohistochemistry, immunocytochemistry, immunoprecipitation

more info or order :

MyBioSource product webpage

product information

catalog number :

MBS2001791

products type :

Antibody

products full name :

Polyclonal Antibody to Procollagen I N-Terminal Propeptide (PINP)

products short name :

[Procollagen I N-Terminal Propeptide (PINP)]

other names :

[collagen alpha-1(I) chain; Collagen alpha-1(I) chain; collagen alpha-1(I) chain; collagen type I alpha 1 chain; Alpha-1 type I collagen]

products gene name :

[PINP]

other gene names :

[Col1a1; Col1a1; COLIA1]

clonality :

Polyclonal

isotype :

IgG

host :

Rabbit

reactivity :

Rat

sequence :

PEEYVSPDAEVIG

specificity :

The antibody is a Rabbit polyclonal antibody raised against PINP. It has been selected for its ability to recognize PINP in immunohistochemical staining and western blotting.

purity :

Antigen-specific affinity chromatography followed by Protein A affinity chromatography

form :

Supplied as solution form in 0.01M PBS, pH7.4, containing 0.05% Proclin-300, 50% glycerol.

concentration :

200ug/ml

storage stability :

Storage: Avoid repeated freeze/thaw cycles. Store at 4ºC for frequent use. Aliquot and store at -20ºC for 12 months. Stability Test: The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37°C for 48h, and no obvious degradation and precipitation were observed. The loss rate is less than 5% within the expiration date under appropriate storage condition.

tested application :

WB; IHC; ICC; IP

app notes :

Immunohistochemistry: 5-20ug/mL. Immunocytochemistry: 5-20ug/mL. Optimal working dilutions must be determined by end user.

other info1 :

Source: Polyclonal antibody preparation. Traits: Liquid. Immunogen: Synthetic Peptide, PINP conjugated to OVA

other info2 :

Conjugated Antibody: The APC conjugated antibody version of this item is also available as catalog #MBS2049984

ncbi gi num :

158711704

ncbi acc num :

NP_445756.1

ncbi gb acc num :

NM_053304.1

uniprot acc num :

P02454

ncbi mol weight :

137,953 Da

ncbi pathways :

AGE-RAGE Signaling Pathway In Diabetic Complications (1320189); AGE-RAGE Signaling Pathway In Diabetic Complications (1319775); Amoebiasis Pathway (167311); Amoebiasis Pathway (167191); Assembly Of Collagen Fibrils And Other Multimeric Structures Pathway (1332740); Cardiovascular Signaling Pathway (219769); Collagen Biosynthesis And Modifying Enzymes Pathway (1332739); Collagen Formation Pathway (1332738); ECM-receptor Interaction Pathway (83460); ECM-receptor Interaction Pathway (479)

ncbi summary :

extracellular matrix collagen protein [RGD, Feb 2006]

uniprot summary :

COL1A1: Type I collagen is a member of group I collagen (fibrillar forming collagen). Defects in COL1A1 are the cause of Caffey disease (CAFFD); also known as infantile cortical hyperostosis. Caffey disease is characterized by an infantile episode of massive subperiosteal new bone formation that typically involves the diaphyses of the long bones, mandible, and clavicles. The involved bones may also appear inflamed, with painful swelling and systemic fever often accompanying the illness. The bone changes usually begin before 5 months of age and resolve before 2 years of age. Defects in COL1A1 are a cause of Ehlers-Danlos syndrome type 1 (EDS1); also known as Ehlers-Danlos syndrome gravis. EDS is a connective tissue disorder characterized by hyperextensible skin, atrophic cutaneous scars due to tissue fragility and joint hyperlaxity. EDS1 is the severe form of classic Ehlers-Danlos syndrome. Defects in COL1A1 are the cause of Ehlers-Danlos syndrome type 7A (EDS7A); also known as autosomal dominant Ehlers-Danlos syndrome type VII. EDS is a connective tissue disorder characterized by hyperextensible skin, atrophic cutaneous scars due to tissue fragility and joint hyperlaxity. EDS7A is marked by bilateral congenital hip dislocation, hyperlaxity of the joints, and recurrent partial dislocations. Defects in COL1A1 are a cause of osteogenesis imperfecta type 1 (OI1). A dominantly inherited connective tissue disorder characterized by bone fragility and blue sclerae. Osteogenesis imperfecta type 1 is non-deforming with normal height or mild short stature, and no dentinogenesis imperfecta. Defects in COL1A1 are a cause of osteogenesis imperfecta type 2 (OI2); also known as osteogenesis imperfecta congenita. A connective tissue disorder characterized by bone fragility, with many perinatal fractures, severe bowing of long bones, undermineralization, and death in the perinatal period due to respiratory insufficiency. Defects in COL1A1 are a cause of osteogenesis imperfecta type 3 (OI3). A connective tissue disorder characterized by progressively deforming bones, very short stature, a triangular face, severe scoliosis, grayish sclera, and dentinogenesis imperfecta. Defects in COL1A1 are a cause of osteogenesis imperfecta type 4 (OI4); also known as osteogenesis imperfecta with normal sclerae. A connective tissue disorder characterized by moderately short stature, mild to moderate scoliosis, grayish or white sclera and dentinogenesis imperfecta. Genetic variations in COL1A1 are a cause of susceptibility to osteoporosis (OSTEOP); also known as involutional or senile osteoporosis or postmenopausal osteoporosis. Osteoporosis is characterized by reduced bone mass, disruption of bone microarchitecture without alteration in the composition of bone. Osteoporotic bones are more at risk of fracture. A chromosomal aberration involving COL1A1 is found in dermatofibrosarcoma protuberans. Translocation t(17;22)(q22;q13) with PDGF. Belongs to the fibrillar collagen family. Protein type: Extracellular matrix; Secreted; Secreted, signal peptide. Chromosomal Location of Human Ortholog: 10q26. Cellular Component: collagen; collagen type I trimer; cytoplasm; endoplasmic reticulum; extracellular matrix; extracellular region; extracellular space; Golgi apparatus; proteinaceous extracellular matrix; secretory granule. Molecular Function: extracellular matrix structural constituent; identical protein binding; metal ion binding; platelet-derived growth factor binding; protease binding; protein binding. Biological Process: blood vessel development; collagen biosynthetic process; collagen fibril organization; embryonic skeletal system development; endochondral ossification; extracellular matrix organization; intramembranous ossification; ossification; osteoblast differentiation; positive regulation of cell migration; positive regulation of transcription, DNA-templated; protein transport; response to cAMP; response to corticosteroid stimulus; response to drug; response to estradiol; response to hydrogen peroxide; response to hyperoxia; response to mechanical stimulus; response to nutrient; response to nutrient levels; response to peptide hormone; response to steroid hormone; sensory perception of sound; skeletal morphogenesis; skeletal system development; skin development; skin morphogenesis; visual perception; wound healing

size1 :

0.01 mg

price1 :

115 USD

size2 :

0.02 mg

price2 :

135

size3 :

0.05 mg

price3 :

190

size4 :

0.1 mg

price4 :

245

size5 :

0.2 mg

price5 :

365

size6 :

1 mg

price6 :

870

more info or order :

MyBioSource product webpage